Adjuvant Pazopanib vs Placebo After Nephrectomy for Localized or Locally Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
J. Clin. Oncol 2017 Sep 13;[EPub Ahead of Print], RJ Motzer, NB Haas, F Donskov, M Gross-Goupil, S Varlamov, E Kopyltsov, JL Lee, B Melichar, BI Rini, TK Choueiri, M Zemanova, LA Wood, MN Reaume, A Stenzl, S Chowdhury, HY Lim, R McDermott, A Michael, W Bao, MJ Carrasco-Alfonso, P Aimone, M Voi, C Doehn, P Russo, CN SternbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.